<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118037</url>
  </required_header>
  <id_info>
    <org_study_id>CL 04878</org_study_id>
    <nct_id>NCT03118037</nct_id>
  </id_info>
  <brief_title>Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry</brief_title>
  <acronym>SAGE</acronym>
  <official_title>Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynesonics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynesonics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SAGE is an observational post market registry with the objective of characterizing long term&#xD;
      outcomes after treatment of uterine fibroids with the Sonata System in real world clinical&#xD;
      practice settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients whom have selected the CE-marked Sonata system for treatment of fibroids will be&#xD;
      approached for study participation. Participation in the trial will consist of data&#xD;
      collection in the form of questionnaires prior to and after the treatment at the following&#xD;
      intervals: pre-procedure, 4 weeks, 1, 2, 3, 4 and 5 years following treatment.&#xD;
&#xD;
      The following data points will be collected: Length of stay, time to return to normal&#xD;
      activities (Treatment Recovery Questionnaire), time to return to sexual activity (Treatment&#xD;
      Recovery Questionnaire), change in fibroid symptom severity and quality of life (UFS-QOL),&#xD;
      change in general health outcome (EQ-5D), work productivity and activity impairment (WPAI),&#xD;
      subject satisfaction and overall treatment effect (Overall Treatment Effect and Satisfaction&#xD;
      Questionnaire), pregnancy occurrence and outcome, non-medical re-intervention, adverse events&#xD;
      related to the device/procedure.&#xD;
&#xD;
      Validated questionnaires are used where appropriate (UFS-QOL, E1-5D and WPAI). Double data&#xD;
      entry will occur to ensure accurate capture of subject reported data. Monitoring will occur&#xD;
      throughout the course of the trial to ensure adherence to the protocol.&#xD;
&#xD;
      As an observational trial, there are no pre-specified statistically powered endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of Pregnancy and Pregnancy Outcomes</measure>
    <time_frame>Up to 5 years-post procedure</time_frame>
    <description>Number of subjects with pregnancy and the number of pregnancies during the 5 year follow-up period. Outcome of each pregnancy including pregnancy outcomes, delivery route, antenatal and perinatal complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical Re-intervention for Heavy Menstrual Bleeding</measure>
    <time_frame>Up to 5 years-post procedure</time_frame>
    <description>Number of subjects who had surgical re-intervention to treat heavy menstrual bleeding during the 5 year follow-up period.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Uterine Fibroid Symptom - Quality of Life</measure>
    <time_frame>Pre-procedure and up to 5 years</time_frame>
    <description>UFS-QoL, validated fibroid specific assessment tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Stay</measure>
    <time_frame>From admission to hospital discharge, up to four weeks.</time_frame>
    <description>Length of stay (in hours) for the treatment of fibroids with the Sonata System (which occurs at enrollment into the registry).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Return to Normal Daily Activity</measure>
    <time_frame>First two weeks post procedure</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Return to Sexual Activity</measure>
    <time_frame>First two weeks post procedure</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in General Health Outcome</measure>
    <time_frame>Pre-procedure and up to 5 years</time_frame>
    <description>EQ-5D standardized instrument for use as a measure of health outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Work Productivity and Activity Impairment</measure>
    <time_frame>Pre-procedure and up to 5 years</time_frame>
    <description>Standardized instrument for assessing activity/productivity impairment, commonly used in health economics outcomes research. The tool measure impairment in percentage.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>At 1 year post procedure and up to 5 years</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Treatment Effect</measure>
    <time_frame>At 1 year post procedure and up to 5 years</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Uterine Fibroid</condition>
  <arm_group>
    <arm_group_label>Sonata</arm_group_label>
    <description>Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sonata System</intervention_name>
    <description>Transcervical access for radiofrequency ablation of uterine fibroids</description>
    <arm_group_label>Sonata</arm_group_label>
    <other_name>Transcervical RF Ablation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who select to have their uterine fibroids treated with the Sonata System&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have selected Sonata for treatment of symptomatic uterine fibroids or is participating&#xD;
             in the OPEN study (Evaluation of Uterine Patency Following Sonography-guided&#xD;
             Transcervical Ablation of Fibroids, NCT02844920, protocol # CL04897) or has completed&#xD;
             participation in the OPEN study within the last 14 months&#xD;
&#xD;
          -  Speaks and reads a language for which questionnaires are available&#xD;
&#xD;
          -  Are greater than or equal to 18 years of age at the time of enrollment&#xD;
&#xD;
          -  Willing and able to read, understand and sign the informed consent form, to&#xD;
             participate in the registry and to adhere to all registry study follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any reason for which, in the opinion of the Investigator, the individual study patient&#xD;
             is not appropriate or suitable for participation in the registry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women with diagnosed uterine fibroids are eligible to participate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taraneh G Farazi, PhD</last_name>
    <phone>6502163878</phone>
    <email>tfarazi@gynesonics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy L Morton, MS</last_name>
    <phone>6502163868</phone>
    <email>tmorton@gynesonics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frauenklinik Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Kempten</city>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Köln-Weyertal gemeinnützige GmbH</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>MarienKrankenhaus Schwerte Frauenklinik</name>
      <address>
        <city>Schwerte</city>
        <zip>58239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Josephs-Hospital Warendorf</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Witten</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Spital Oberengadin</name>
      <address>
        <city>Samedan</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariam Baumgarten, MD</last_name>
      <email>miriam.baumgarten@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adel Soltan, MD</last_name>
      <email>Adel.Soltan@lwh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zaleplon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

